The fully linked HTML version of this article has now been published.
Development ePress online publication date 13 Apr 2005
doi: 10.1242/dev.01824
Research article
The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor
Jill Wildonger
and
Richard S. Mann*
* Author for correspondence (e-mail: rsm10{at}columbia.edu)
The human translocation (t8;21) is associated with
12% of the cases of acute myelogenous leukemia. Two genes, AML1 and ETO, are fused together at the translocation breakpoint, resulting in the expression of a chimeric protein called AML1-ETO. AML1-ETO is thought to interfere with normal AML1 function, although the mechanism by which it does so is unclear. Here, we have used Drosophila genetics to investigate two models of AML1-ETO function. In the first model, AML1-ETO is a constitutive transcriptional repressor of AML1 target genes, regardless of whether they are normally activated or repressed by AML1. In the second model, AML1-ETO dominantly interferes with AML1 activity by, for example, competing for a common co-factor. To discriminate between these models, the effects of expressing AML1-ETO were characterized and compared with loss-of-function phenotypes of lozenge (lz), an AML1 homolog expressed during Drosophila eye development. We also present results of genetic interaction experiments with AML1 co-factors that are not consistent with AML1-ETO behaving as a dominant-negative factor. Instead, our data suggest that AML1-ETO acts as a constitutive transcriptional repressor.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Osman, V. Gobert, F. Ponthan, O. Heidenreich, M. Haenlin, and L. Waltzer
A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO
PNAS,
July 21, 2009;
106(29):
12043 - 12048.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Roudaia, M. D. Cheney, E. Manuylova, W. Chen, M. Morrow, S. Park, C.-T. Lee, P. Kaur, O. Williams, J. H. Bushweller, et al.
CBF{beta} is critical for AML1-ETO and TEL-AML1 activity
Blood,
March 26, 2009;
113(13):
3070 - 3079.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. Cheng, L. Li, S. H. Cheng, K. M. Lau, N. P. H. Chan, R. S. M. Wong, M. M. K. Shing, C. K. Li, and M. H. L. Ng
Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia
Blood,
October 15, 2008;
112(8):
3391 - 3402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Choi, K. E. Elagib, L. L. Delehanty, and A. N. Goldfarb
Erythroid Inhibition by the Leukemic Fusion AML1-ETO Is Associated with Impaired Acetylation of the Major Erythroid Transcription Factor GATA-1.
Cancer Res.,
March 15, 2006;
66(6):
2990 - 2996.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2005